-

09:57:57 AM

THRX Stock News

THRX - Theseus Pharmaceuticals Inc

05/31/23 7:00 AM

Nasdaq : THRX

conferenceslow float

Theseus Pharmaceuticals to Participate in the Jefferies Healthcare Conference

Theseus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced that the company will participate in a live Fireside Chat at the Jefferies...

RHEA-AI

neutral

05/25/23 5:01 PM

Nasdaq : THRX

clinical triallow float

Theseus Pharmaceuticals Reports Initial Dose Escalation Data from Ongoing Phase 1/2 Trial of THE-630 in Patients with Advanced GIST

Theseus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative...

RHEA-AI

neutral

05/11/23 7:00 AM

Nasdaq : THRX

earningslow float

Theseus Pharmaceuticals Announces Business Highlights and Reports First Quarter 2023 Financial Results

Theseus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of...

RHEA-AI

neutral

04/26/23 10:05 AM

Nasdaq : THRX

clinical triallow float

Theseus Pharmaceuticals Initial Dose Escalation Results from Ongoing Phase 1/2 Trial of THE-630 Accepted for Online Publication at 2023 ASCO Annual Meeting

Theseus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies, today announced that initial dose escalation data from the ongoing phase 1/ 2 study of THE-630 in advanced gastrointestinal...

RHEA-AI

neutral

04/11/23 7:00 AM

Nasdaq : THRX

conferenceslow float

Theseus Pharmaceuticals to Participate in Upcoming Investor Conferences

Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted

RHEA-AI

neutral

03/28/23 7:00 AM

Nasdaq : THRX

conferenceslow float

Theseus Pharmaceuticals to Participate in the Cantor Future of Oncology Virtual Symposium

Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies,

RHEA-AI

neutral

03/09/23 7:00 AM

Nasdaq : THRX

earningslow float

Theseus Pharmaceuticals Announces Business Highlights and Reports Fourth Quarter and Full Year 2022 Financial Results

THE-630 phase 1 preliminary dose-escalation data anticipated in Q2 2023; additional data including dose levels projected preclinically to provide pan-variant KIT coverage planned for Q4 2023IND submission expected in Q4 2023 for THE-349 in EGFR-mutant NSCLCBCR-ABL prioritized as third development

RHEA-AI

neutral

02/07/23 7:00 AM

Nasdaq : THRX

conferenceslow float

Theseus Pharmaceuticals to Participate in the SVB Securities Global Biopharma Conference

Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today

RHEA-AI

neutral

01/05/23 7:00 AM

Nasdaq : THRX

low float

Theseus Pharmaceuticals Highlights Key Anticipated 2023 Milestones and Announces BCR-ABL as Target for Third Development Program

Progressing Phase 1/2 clinical trial of THE-630 in advanced GIST; preliminary dose-escalation data anticipated in Q2 2023 with additional data expected in Q4 2023IND submission for 4G EGFR inhibitor THE-349 expected in Q4 2023Introducing BCR-ABL as target for third program, in development for CML

RHEA-AI

positive

11/03/22 8:36 AM

Nasdaq : THRX

earningslow float

Theseus Pharmaceuticals Announces Business and Pipeline Highlights and Reports Third Quarter 2022 Financial Results

All sites open and actively enrolling in Phase 1 portion of Phase 1/2 clinical trial of THE-630 in advanced GIST; preliminary dose escalation data expected in Q2 2023Preclinical data characterizing THE-349 in EGFR-mutant NSCLC presented at 2022 EORTC-NCI-AACR Symposium; IND application submission

RHEA-AI

neutral

THRX Data

IndustryPharmaceutical Preparation Manufacturing
Websitetheseusrx.com
Security nameTheseus Pharmaceuticals Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees26

About Theseus Pharmaceuticals Inc

Theseus is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Theseus is developing next-generation tyrosine kinase inhibitors (TKIs): "pan-variant" targeted therapies that address all major drug resistance mutations. Theseus' lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC).